Nordic Walking for Diabetes: Do Poles Lower HbA1c More?

Nordic walking may lower HbA1c modestly in people with type 2 diabetes, but nobody has shown that the poles deserve the credit. The best available review found a 0.37-percentage-point reduction in HbA1c versus sedentary or usual-care control groups. It did not compare Nordic walking with regular walking matched for pace, duration, or weekly training time. That missing comparison changes the practical question from "Do poles work?" to "Are poles worth the extra hassle for you?"

The answer is more useful than dramatic. If poles make you walk farther, faster, or more consistently, they may help. If they stay in the closet because the technique feels awkward, ordinary walking is likely the better metabolic tool. The current trials cannot tell us whether pole use adds anything beyond the exercise itself.

The headline number measures walking versus little or no walking

A 2026 systematic review and meta-analysis by Chen et al. pooled six randomized controlled trials in adults with prediabetes or type 2 diabetes. Nordic walking lowered HbA1c by a weighted mean difference of 0.37 percentage points and raised HDL cholesterol by 0.07 mmol/L. The review found no statistically significant changes in fasting glucose, HOMA-IR, LDL cholesterol, total cholesterol, body mass index, or waist circumference.

Those are the only pooled randomized estimates specific to Nordic walking in diabetes and prediabetes. Yet every included control group received sedentary care or usual care rather than an intensity-matched regular-walking program. The result therefore estimates the effect of a structured Nordic-walking program compared with doing less structured exercise. It does not estimate the metabolic effect of adding poles to an otherwise identical walk.

The review also reported substantial inconsistency among the HbA1c results: I² was 69%. That statistic does not invalidate the average outright, but it warns against treating 0.37% as a precise, universal result. The trials differed in population, baseline glucose status, and duration, including one intervention that lasted only four weeks. HbA1c reflects average blood glucose over roughly the prior two to three months, so a four-week program is a poor fit for that endpoint.

Type 2 diabetes and prediabetes should not be bundled together

The largest and longest trial described in the review points to baseline glycemic status as a major reason the results vary. In the Swedish Fritz et al. trial, 85 participants completed about 16 weeks of Nordic walking at roughly five hours per week. Participants with type 2 diabetes improved HbA1c, while the impaired-glucose-tolerance or prediabetes subgroup showed no HbA1c effect. The comparator was sedentary control, not regular walking.

That subgroup split makes it hard to apply the pooled 0.37% result to prediabetes. It also fits the broader pattern: two earlier Nordic-walking meta-analyses cited by Chen et al.—one covering eight randomized trials in 465 adults with overweight or obesity and another covering 22 trials in 1,271 older adults with a mean age of 62—found no HbA1c benefit.

A reasonable explanation is room to improve. People with established type 2 diabetes generally begin with higher HbA1c than people with prediabetes, so an exercise program has more opportunity to shift the marker. That is an inference from the population pattern, not proof that pole-assisted arm work has no special effect.

For prediabetes, poles clearly are not required for a structured exercise program to help. A 2025 randomized trial by Hafeez et al. reported improved biochemical markers, including HbA1c, after an exercise manual program in sedentary people with prediabetes. The intervention did not use poles. It cannot prove that regular walking equals Nordic walking, but it does show that a pole-free structured program can improve glycemic markers in this population.

More muscle use is plausible, but it is not a clinical comparison

Nordic walking recruits the upper body and is estimated to engage 70% to 90% of skeletal muscle mass, compared with roughly 50% during regular walking. More active muscle could increase glucose uptake after exercise, especially after meals. That mechanism is biologically plausible.

It is not, however, evidence that poles produce a larger HbA1c reduction than regular walking. The diabetes and prediabetes evidence contains no direct study measuring oxygen consumption or kilocalorie expenditure for Nordic versus regular walking when session length and frequency are matched. Without that measurement, claims that poles add a specific calorie advantage cannot be weighed against the actual glycemic data.

The pattern of outcomes offers a hypothesis rather than an answer. HbA1c improved in the pooled analysis while fasting glucose and HOMA-IR did not. That could reflect changes in post-meal glucose disposal rather than a meaningful improvement in fasting insulin sensitivity or hepatic insulin resistance. The included trials did not directly test that pathway.

How much clinical value does a 0.37% HbA1c change have?

For perspective, a 2024 meta-analysis of high-intensity interval training in type 2 diabetes reported HbA1c reductions of 0.4% to 0.8%, depending on the program. Nordic walking's 0.37% estimate sits at the lower edge of that range. It is consistent with a modest effect from structured aerobic activity, not evidence that Nordic walking is an optimized glucose-lowering treatment.

A 2026 review of low-intensity endurance training also supports the broader physiological point: aerobic training can improve cardiometabolic risk factors through skeletal-muscle pathways. It does not establish that Nordic walking has an advantage over conventional walking.

The HDL result deserves similar restraint. A 0.07 mmol/L increase falls below the roughly 0.15 to 0.20 mmol/L threshold often used as a minimally clinically important difference. It is a small biomarker change, not evidence of fewer heart attacks or longer life.

HbA1c itself is a surrogate marker. A 2023 systematic review by Huang et al., using causal directed acyclic graph methods to examine type 2 diabetes trials, concluded that intensive HbA1c lowering may contribute less to cardiovascular protection than once assumed. That does not make HbA1c irrelevant, but it makes it harder to claim that a 0.37% change will alter long-term cardiovascular outcomes.

Short trials cannot answer the durability question

The Nordic-walking trials ran for roughly four to 24 weeks, which is enough to detect short-term biomarker movement but not enough to establish durable benefit. The six-year follow-up of the U-TURN lifestyle trial provides a sobering comparison. In people with type 2 diabetes, benefits from a far more intensive, year-long lifestyle intervention attenuated after the formal program ended.

Nordic walking does not get a special exemption from that rule. Any benefit depends on continued participation. The published Nordic-walking review also leaves practical questions open: it does not provide enough evidence on adherence, dropout, or injuries in older adults or people with diabetic neuropathy.

A 2024 randomized trial in older adults adds another caution. Health changes depended on iron status, and the combination of Nordic walking with time-restricted eating produced changes that Nordic walking alone did not. This does not prove that every older adult needs dietary restriction to benefit from walking. It does show that Nordic walking by itself did not reliably clear a meaningful metabolic threshold in that trial.

Should you use the poles?

For established type 2 diabetes, Nordic walking is a reasonable way to make aerobic exercise more engaging or stable. The available randomized evidence supports a modest HbA1c improvement compared with sedentary or usual care. It does not support a claim that poles lower HbA1c more than an equivalent dose of regular walking.

For prediabetes, the Nordic-walking evidence is weaker: the highest-dose, longest-duration trial described above found no HbA1c improvement in its impaired-glucose-tolerance subgroup. Choose a structured activity you will repeat—brisk walking, cycling, resistance training, or Nordic walking if you enjoy it—and pair it with the dietary and medical plan appropriate for your risk level.

The poles may be useful equipment for adherence, stability, or exercise intensity. They are not yet proven metabolic equipment.

If poles make your walks longer and more regular, use them. If they add friction, skip them and walk. The metabolic case for consistency is far stronger than the metabolic case for the poles.